PIC Therapeutics develops small molecule precision therapeutics that modulate the Pre-Initiation Complex to selectively inhibit oncogene protein production in cancer cells. This approach targets the underlying mechanisms of therapeutic resistance and tumor complexity, aiming to improve treatment efficacy for patients with unmet medical needs.
Funding
$46.5M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many cancer treatments lose efficacy over time due to therapeutic resistance and tumor complexity. Current therapies often fail to address the underlying mechanisms driving oncogene protein production, leading to disease progression and unmet medical needs.
Solution
PIC Therapeutics is developing small molecule precision therapeutics that selectively inhibit oncogene protein production in cancer cells by modulating the Pre-Initiation Complex (PIC). This approach targets the "master switch" of cancer signaling pathways, potentially overcoming therapeutic resistance and addressing tumor complexity. By selectively blocking oncogene protein production, PIC Therapeutics aims to simultaneously modulate multiple oncogenic drivers, leading to a new generation of cancer-treating therapeutics. This precision-based approach is designed to improve individual patient outcomes by addressing the limitations of currently available treatments.
Target Audience
The primary target audience includes cancer patients with unmet medical needs and healthcare providers seeking more effective and durable treatment options.
Features
- Small molecule therapeutics designed for precision targeting of the Pre-Initiation Complex (PIC).
- Selective inhibition of oncogene protein production to disrupt cancer signaling pathways.
- Modulation of RNA translation to address therapeutic resistance mechanisms.
- Potential to simultaneously modulate multiple oncogenic drivers for enhanced efficacy.